Pharmacokinetic interaction of nelfinavir and methadone in intravenous drug users

Biopharmaceutics and Drug Disposition

Volumn 27, Issue 2, 2006, Pages 61-68

  Hsyu, Poe Hirr ^a   Lillibridge, Jim ^b   Daniels, Elaine ^c   Kerr, Bradley M ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b AMGEN INC   (United States)

^c PFIZER INC   (United States)

Author keywords

Drug interaction; HIV; Withdrawal symptoms

Indexed keywords

METHADONE; NELFINAVIR;

ADULT; ANALYSIS OF VARIANCE; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG DOSE REDUCTION; DRUG HALF LIFE; ENANTIOMER; FEMALE; GENOTYPE; HEADACHE; HUMAN; HYPERLIPIDEMIA; INTESTINAL DYSMOTILITY; INTRAVENOUS DRUG ABUSE; LIVER TOXICITY; MAINTENANCE DRUG DOSE; MALE; MASS SPECTROMETRY; OPEN STUDY; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; TABLET FORMULATION;

ADMINISTRATION, ORAL; ADULT; DRUG INTERACTIONS; FEMALE; HIV PROTEASE INHIBITORS; HUMANS; MALE; METHADONE; MIDDLE AGED; NARCOTICS; NELFINAVIR; PROSPECTIVE STUDIES; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 33645315504     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.482     Document Type: Article

References (23)

1. Drug-Associated HIV Transmission Continues in the United States: U.S. Center for Disease Control and Prevention Internet site, http://www.cdc.gov/hiv/pubs/facts/idu.htm. Accessed June, 2005.
2. U.S. National Institutes of Health Consensus Conference. Effective medical treatment of opiate addiction. JAMA 1998; 280: 1936-1943.
3. Murray JB. Effectiveness of methadone maintenance for heroin addiction. Psychol Rep 1998; 83: 295-302.
4. Marsch LA. The efficacy of methadone maintenance interventions in reducing illicit opiate use, HIV risk behavior and criminality: a meta-analysis. Addiction 1998; 93: 515-532.
5. Iribarne C, Berthou F, Baird S, et al. Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes. Chem Res Toxicol 1996; 9: 365-373.
6. Moody DE, Alburges ME, Parker RJ, et al. The involvement of cytochrome P4503A4 in the N-demethylation of L-α-acetylmethadol (LAAM), norLAAM, and methadone. Drug Metab Dispos 1997; 25: 1347-1353.
7. Iribarne C, Berthou F, Carlhant D, et al. Inhibition of methadone and buprenorphine N-dealkylations by three HIV-1 protease inhibitors. Drug Metab Dispos 1998; 26: 257-260.
8. Gerber Jg, Rhodes RJ, Gal J. Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19. Chirality 2004; 16: 36-44.
9. Package insert of Viracept (nelfinavir mesylate), 2004.
10. Zhang KF, Wu E, Patick AK, et al. Circulating metabolites of the human immunodeficiency virus protease inhibitor nelfinavir in humans: structure identification, levels in the plasma, and antiviral activities. Antimicrob Agents Chemother 2001; 45: 1086-1093.
11. Hsyu PH, Schultz-Smith M, Lillibridge J, Lewis R, Kerr BM. Pharmacokinetic interactions between nelfinavir and HMG-Co reductase inhibitors atorvastatin and simvastatin. Antimicrob Agents Chemother 2001; 45: 3445-3450.
12. Clarke SM, Mulcahy FM, Tjia J, et al. The pharmacokinetics of methadone in HIV-positive patients receiving the nonnucleoside reverse transcriptase inhibitor efavirenz. Br J Clin Pharmacol 2001; 51: 213-217.
13. Clarke SM, Mulcahy FM, Tjia J, et al. Pharmacokinetics interactions of nevirapine and methadone and guidelines for use of nevirapine to treat injection drug users. Clin Infect Dis 2001; 33: 1595-1597.
14. Altice FL, Friedland GH, Cooney EL. Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone. AIDS 1999; 13: 957-962.
15. Clarke SM, Mulcahy FM, Bergin C, et al. Absence of opioid withdrawal symptoms in patients receiving methadone and the protease inhibitor lopinavir-ritonavir. Clin Infect Dis 2001; 34: 1143-1145.
16. Gerber JG, Rosenkranz S, Segal Y, et al. Effect of ritonavir/saquinavir on stereoselective pharmacokinetics of methadone: results of AIDS clinical trials group (ACTG) 401. J AIDS 2001; 27: 153-160.
17. McCane-Katz EF, Rainey PM, Friedland G, Jatlow P. The protease inhibitor lopinavir-ritonavir may produce opiate withdrawal in the methadone-maintained patients. Clin Infect Dis 2003; 37: 476-482.
18. McCane-Katz EF, Rainey PM, Smith P, et al. Drug interactions between opioids and antiretroviral medications: interaction between methadone, LAAM, and nelfinavir. Am J Addict 2004; 13: 163-180.
19. 1-acid glycoprotein. Clin Pharmacol Ther 1990; 47: 338-346.
20. Package insert of Viramune (nevirapine), Boehringer Ingelheim Pharmaceuticals Inc., 2005.
21. Package insert of Sustiva (efavirenz), Bristol-Myers Squibb Company, 2004.
22. Eap CB, Broly F, Mino A, et al. Cytochrome P450 2D6 genotype and methadone steady-state concentrations. Clin Psychopharmacol 2001; 21: 229-234.
23. Kharasch ED, Hoffer C, Whittington D. The effect of quinidine, used as a probe for the involvement of p-glycoprotein, on the intestinal absorption and pharmacodynamic of methadone. Br J Clin Pharmacol 2004; 57: 600-610.